SPRY2 functions as a tumor suppressor in most cancers and its expression has been found to be low in a variety of cancers, such as prostate cancer [69], breast cancer [70], lung cancer [71], liver cancer [33] and colon cancer [72]. Here, SPRY2 is linked to prostate cancer.